EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action?

Diabetologia

Volumn 59, Issue 6, 2016, Pages 1145-1147

  Bugianesi, Elisabetta ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Cost effectiveness; Fatty liver; Guidelines; Screening

Indexed keywords

HUMAN; NONALCOHOLIC FATTY LIVER;

HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84962708348     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-3930-7     Document Type: Article

References (12)

1. Yki-Järvinen H (2014) Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol 2:901–910
2. Bhala N, Jouness RI, Bugianesi E (2013) Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 19:5169–5176
3. Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62:S47–S64
4. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13:643–654
5. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Diabetologia. doi:10.1007/s00125-016-3902-y
6. Kwok R, Choi KC, Wong GL et al (2015) Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. doi:10.1136/gutjnl-2015-309265
7. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P (2013) A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 58:1218–1229
8. Crossan C, Tsochatzis EA, Longworth L et al (2015) Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technol Assess 19:1–409. doi:10.3310/hta19090, v-vi
9. Corey KE, Klebanoff MJ, Tramontano AC, Chung RT, Hur C (2016) Screening for nonalcoholic steatohepatitis in individuals with type 2 diabetes: a cost-effectiveness analysis. Dig Dis Sci 29: doi: 10.1007/s10620-016-4044-2
10. Prati D, Taioli E, Zanella A et al (2001) Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 137:1–10
11. Schwimmer JB, Dunn W, Norman GJ et al (2010) SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterology 138:1357–1364
12. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado (2015) EASL–ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 63:237–264